LX1001
gene therapy · Lexeo Therapeutics · Restore protective APOE
Current state
- Status
- Phase 1 — 1 active of 2 tracked studies
- Sponsor
- Lexeo Therapeutics
- Modality
- gene therapy
- Mechanism
- AAVrh.10 APOE2 delivery
- Thesis
- Restore protective APOE
- Record checked
- Verified by a curator
- Last change
- no change event observed since tracking began
- Last reviewed
- (2 days ago)
Trials — 2
| NCT | Title | Phase | Status | Start | Primary completion | N | APOE-strat. |
|---|---|---|---|---|---|---|---|
| NCT03634007 | Gene Therapy for APOE4 Homozygote of Alzheimer's Disease | PHASE1/PHASE2 | COMPLETED | 15 | no | ||
| NCT05400330 | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease | PHASE1 | ACTIVE_NOT_RECRUITING | 10 | no |
Publications — 0
No linked publication. Nothing has been resolved to this therapeutic in Europe PMC or OpenAlex. Where nobody has checked the record yet, this usually means the identifier is used inconsistently in the literature rather than that no work exists.
Change history — 0
No changes detected for LX1001 as of the snapshot taken .
This is not the same as nothing having happened. The oldest source in this snapshot last succeeded (2 days ago), and registry and filing data lag the events they describe. See methodology.